Review
BibTex RIS Cite

Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi

Year 2019, Volume: 12 Issue: 1, 136 - 142, 28.04.2019
https://doi.org/10.26559/mersinsbd.474682

Abstract



Bu derlemede, tarihsel bir yaklaşımla, talidomit kullanan
gebelerin fokomelili bebeklerinin doğumu sonrasında yaşananlar
değerlendirilerek, bu facianın sistematik farmakovijilans etkinliklerinin
gelişimine etkisi araştırılmıştır. Bu amaçla, ilgili anahtar kelimeleri içeren
PubMed taraması yapılarak çalışmamızın amacı ile uyumlu bilimsel makaleler ve
tarihsel bilgileri içeren derlemeler çalışmamıza dahil edilmiştir. Bulgularımız
teratojenisite, ilaç güvenliliği ile ilgili etik ve yasal düzenlemeler, ilaçların
geliştirilmesi ve pazarlama sonrası gözetimi gibi önemli farmakovijilans
etkinliklerinin gelişiminde talidomit faciasının nasıl bir itici güç olduğunu
vurgulamıştır. Talidomidin kütanöz lepranın ve multipl myelomanın tedavisinde
kullanılmak üzere yakın geçmişte ilaç piyasasına geri dönüşü ilaç güvenliliğine
bakış açımızı değiştirmiş ve risk yönetimini ön plana çıkartmıştır. Sonuç
olarak; talidomit faciasının ardından yaşananlara günümüzün gözüyle bakmak,
farmakovijilans etkinliklerini daha iyi anlamamızı sağlamakla birlikte
önümüzdeki yıllarda farmakovijilansı bekleyen zorlukları belirleyip çözmemize
yardımcı olma potansiyelini de taşımaktadır. 

References

  • 1. World Health Organization. The Importance of Pharmacovigilance. Erişim yeri: http://apps.who.int/medicinedocs/en/d/Js4893e/, Erişim tarihi: 2.10.2018.
  • 2. Pharmacovigilance Risk Assessment Committee: PRAC strategy on measuring the impact of Pharmacovigilance activities. Erişim yeri: http://www.ema.europ a.eu/docs/en_GB/docum ent_libra ry/Other/2016/01/WC500 19975 6.pdf, Erişim tarihi: 2.10.2018.
  • 3. James HK, Anthony RS. Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease. Tox Sci 2011;122(1); 1–6.
  • 4. Mellin GW, Katzenstein M. The saga of thalidomide: neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962; 267: 1184–92.
  • 5. Vargesson N. The teratogenic effects of thalidomide on limbs. J Hand Surg Eur 2018 Vol. 2018; 1753193418805249.
  • 6. Schumacher HA. Comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 1968; 160; 189–199.
  • 7. McFadyen R. Thalidomide in America: A brush with tragedy. Clio Medica 1976; 11: 79-93.
  • 8. Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38: 203–15.
  • 9. Smithells RW, Newman CHG. Recognition of thalidomide defects. J Med Genet 1992; 29:716-723.
  • 10. Lenz W, Knapp K. Foetal malformations due to Thalidomide. German Med 1962;7:253–8.
  • 11. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961; ii:1358.
  • 12. Curran, W. The thalidomide tragedy in Germany: The end of a historic medicolegal trial. New Engl J Med, 1971; 284: 481-482.
  • 13. Kelsey, F. Thalidomide update: regulatory aspects. Teratology 1988; 38: 221–226.
  • 14. Lenz, W. Malformations caused by drugs in pregnancy. Am J Dis Child, 1966; 112: 99-106.
  • 15. Lenz W. 1962. Thalidomide and congenital abnormalities [letter]. Lancet 279:303–305.
  • 16. Newman CGH. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol 1986; 13:555-573.
  • 17. Vargesson N. Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140 – 156.
  • 18. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303–306.
  • 19. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis 1969; 37: 135–146.
  • 20. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085.
  • 21. Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971–78.
  • 22. Uhl K, Cox E, Rogan R, Zeldis JB, Hixon D. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf 2006;29:321–329.
  • 23. Patient Guide to (THALOMID REMS™) Risk Evaluation and Mitigation Strategy (REMS)™ Program. Erişim yeri: https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm361111.htm, Erişim tarihi: 23.10.2018
  • 24. Wells PG. A new target for thalidomide. Nat Chem Biol 2018;14(10):904-905.
  • 25. YellowCard. Erişim yeri:https://yellowcard.mhra.gov.uk/monitoring safety/.Erişim tarihi: 20.10.2018.
  • 26. Dally A. Thalidomide: was the tragedy preventable? Lancet 1998;351: 1197-1199.
  • 27. Buharalioglu CK, Acar S, Erol-Coskun H, Küçüksolak G, Karadas B, Kaya-Temiz T, Kaplan YC. Pregnancy outcomes after maternal betahistine exposure: A case series. Reprod Toxicol 2018;79:79-83.
  • 28. George J. Annas, JD, Sherman E. Thalidomide and the Titanic: Reconstructing the Technology Tragedies of the Twentieth Century. Am J Public Health 1999;89(1): 98-101.
  • 29. Ahmed M, Hwang JH, Choi S, Han D. Safety classification of herbal medicines used among pregnant women in Asian countries: a systematic review. BMC Complement Altern Med. 2017;17(1):489.

Effects of thalidomide disaster on the development of pharmacovigilance activities

Year 2019, Volume: 12 Issue: 1, 136 - 142, 28.04.2019
https://doi.org/10.26559/mersinsbd.474682

Abstract



In this review, the
effects of thalidomide babies on the development of systematic
pharmacovigilance activities were searched with historical perspective. For
this purpose, after PubMed search with relevant keywords, scientific studies
that serve our purpose were included and historical information was obtained
from the reviews. Our results underlied the fact that thalidomide disaster was
the main driving force for the development of important pharmacovigilance
activities such as teratogenicity, ethical and legal regulations on drug
safety, drug development and post-marketing drug surveillance. Currently, the
return of thalidomide in the treatment of cutaneous leprosy and multiple
myeloma has changed our view on drug safety and highlighted the importance of risk
management. As a result, looking at the thalidomide disaster from today’s
perspective will help us not only to better understand pharmacovigilance
activities but also to identify and solve the challenges that are waiting in
the coming years.

References

  • 1. World Health Organization. The Importance of Pharmacovigilance. Erişim yeri: http://apps.who.int/medicinedocs/en/d/Js4893e/, Erişim tarihi: 2.10.2018.
  • 2. Pharmacovigilance Risk Assessment Committee: PRAC strategy on measuring the impact of Pharmacovigilance activities. Erişim yeri: http://www.ema.europ a.eu/docs/en_GB/docum ent_libra ry/Other/2016/01/WC500 19975 6.pdf, Erişim tarihi: 2.10.2018.
  • 3. James HK, Anthony RS. Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease. Tox Sci 2011;122(1); 1–6.
  • 4. Mellin GW, Katzenstein M. The saga of thalidomide: neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962; 267: 1184–92.
  • 5. Vargesson N. The teratogenic effects of thalidomide on limbs. J Hand Surg Eur 2018 Vol. 2018; 1753193418805249.
  • 6. Schumacher HA. Comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 1968; 160; 189–199.
  • 7. McFadyen R. Thalidomide in America: A brush with tragedy. Clio Medica 1976; 11: 79-93.
  • 8. Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38: 203–15.
  • 9. Smithells RW, Newman CHG. Recognition of thalidomide defects. J Med Genet 1992; 29:716-723.
  • 10. Lenz W, Knapp K. Foetal malformations due to Thalidomide. German Med 1962;7:253–8.
  • 11. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961; ii:1358.
  • 12. Curran, W. The thalidomide tragedy in Germany: The end of a historic medicolegal trial. New Engl J Med, 1971; 284: 481-482.
  • 13. Kelsey, F. Thalidomide update: regulatory aspects. Teratology 1988; 38: 221–226.
  • 14. Lenz, W. Malformations caused by drugs in pregnancy. Am J Dis Child, 1966; 112: 99-106.
  • 15. Lenz W. 1962. Thalidomide and congenital abnormalities [letter]. Lancet 279:303–305.
  • 16. Newman CGH. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol 1986; 13:555-573.
  • 17. Vargesson N. Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140 – 156.
  • 18. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303–306.
  • 19. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis 1969; 37: 135–146.
  • 20. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085.
  • 21. Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971–78.
  • 22. Uhl K, Cox E, Rogan R, Zeldis JB, Hixon D. Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme. Drug Saf 2006;29:321–329.
  • 23. Patient Guide to (THALOMID REMS™) Risk Evaluation and Mitigation Strategy (REMS)™ Program. Erişim yeri: https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm361111.htm, Erişim tarihi: 23.10.2018
  • 24. Wells PG. A new target for thalidomide. Nat Chem Biol 2018;14(10):904-905.
  • 25. YellowCard. Erişim yeri:https://yellowcard.mhra.gov.uk/monitoring safety/.Erişim tarihi: 20.10.2018.
  • 26. Dally A. Thalidomide: was the tragedy preventable? Lancet 1998;351: 1197-1199.
  • 27. Buharalioglu CK, Acar S, Erol-Coskun H, Küçüksolak G, Karadas B, Kaya-Temiz T, Kaplan YC. Pregnancy outcomes after maternal betahistine exposure: A case series. Reprod Toxicol 2018;79:79-83.
  • 28. George J. Annas, JD, Sherman E. Thalidomide and the Titanic: Reconstructing the Technology Tragedies of the Twentieth Century. Am J Public Health 1999;89(1): 98-101.
  • 29. Ahmed M, Hwang JH, Choi S, Han D. Safety classification of herbal medicines used among pregnant women in Asian countries: a systematic review. BMC Complement Altern Med. 2017;17(1):489.
There are 29 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Articles
Authors

Cüneyt Kemal Buharalıoğlu 0000-0001-6077-1550

Gökçe Yıldırım Buharalıoğlu This is me 0000-0002-4277-0084

Publication Date April 28, 2019
Submission Date October 25, 2018
Acceptance Date December 24, 2018
Published in Issue Year 2019 Volume: 12 Issue: 1

Cite

APA Buharalıoğlu, C. K., & Yıldırım Buharalıoğlu, G. (2019). Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi. Mersin Üniversitesi Sağlık Bilimleri Dergisi, 12(1), 136-142. https://doi.org/10.26559/mersinsbd.474682
AMA Buharalıoğlu CK, Yıldırım Buharalıoğlu G. Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi. Mersin Univ Saglık Bilim derg. April 2019;12(1):136-142. doi:10.26559/mersinsbd.474682
Chicago Buharalıoğlu, Cüneyt Kemal, and Gökçe Yıldırım Buharalıoğlu. “Talidomit faciasının Farmakovijilans Etkinliklerinin gelişimi üzerine Etkisi”. Mersin Üniversitesi Sağlık Bilimleri Dergisi 12, no. 1 (April 2019): 136-42. https://doi.org/10.26559/mersinsbd.474682.
EndNote Buharalıoğlu CK, Yıldırım Buharalıoğlu G (April 1, 2019) Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi. Mersin Üniversitesi Sağlık Bilimleri Dergisi 12 1 136–142.
IEEE C. K. Buharalıoğlu and G. Yıldırım Buharalıoğlu, “Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi”, Mersin Univ Saglık Bilim derg, vol. 12, no. 1, pp. 136–142, 2019, doi: 10.26559/mersinsbd.474682.
ISNAD Buharalıoğlu, Cüneyt Kemal - Yıldırım Buharalıoğlu, Gökçe. “Talidomit faciasının Farmakovijilans Etkinliklerinin gelişimi üzerine Etkisi”. Mersin Üniversitesi Sağlık Bilimleri Dergisi 12/1 (April 2019), 136-142. https://doi.org/10.26559/mersinsbd.474682.
JAMA Buharalıoğlu CK, Yıldırım Buharalıoğlu G. Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi. Mersin Univ Saglık Bilim derg. 2019;12:136–142.
MLA Buharalıoğlu, Cüneyt Kemal and Gökçe Yıldırım Buharalıoğlu. “Talidomit faciasının Farmakovijilans Etkinliklerinin gelişimi üzerine Etkisi”. Mersin Üniversitesi Sağlık Bilimleri Dergisi, vol. 12, no. 1, 2019, pp. 136-42, doi:10.26559/mersinsbd.474682.
Vancouver Buharalıoğlu CK, Yıldırım Buharalıoğlu G. Talidomit faciasının farmakovijilans etkinliklerinin gelişimi üzerine etkisi. Mersin Univ Saglık Bilim derg. 2019;12(1):136-42.

MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.

Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.

Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.

Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.

Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.

Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.

154561545815459

Creative Commons Lisansı
This work is licensed with Attribution-NonCommercial 4.0 International.